The companies said Translate Bio would work on discovering,
designing, and manufacturing a number of SARS-CoV-2 vaccine
candidates, while Sanofi would provide its expertise in the field of
vaccines and support from its research networks.
"We are committed to leveraging different ways to address the
COVID-19 public health crisis by testing treatments, as well as two
vaccines using different platforms," said David Loew, Global Head of
Vaccines at Sanofi, in a statement
[to top of second column] |
"We believe the more approaches we explore, the better our likelihood of success
in achieving this goal."
(Reporting by Sudip Kar-Gupta; Editing by Shri Navaratnam)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |